131 related articles for article (PubMed ID: 1969379)
21. Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer--a study on 674 patients.
Takahashi K; Shibukawa T; Moriyama M; Shirai T; Kijima S; Iwanari O; Matsunaga I; Kitao M
Jpn J Surg; 1986 Sep; 16(5):305-10. PubMed ID: 3467109
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
Inoue M; Ogawa H; Nakanishi K; Tanizawa O; Karino K; Endo J
Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
[TBL] [Abstract][Full Text] [Related]
24. [Tumor markers of ovarian cancer].
Nozawa S
Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
[TBL] [Abstract][Full Text] [Related]
25. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
[TBL] [Abstract][Full Text] [Related]
26. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
27. [The clinical value of sialyl SSEA-1 antigen in patients with gynecologic tumors].
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saitoh J; Ueda G; Tanizawa O; Kimura T; Kawata M; Taniguchi T
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Dec; 39(12):2120-4. PubMed ID: 2892886
[TBL] [Abstract][Full Text] [Related]
28. The CA 125 tumour-associated antigen: a review of the literature.
Jacobs I; Bast RC
Hum Reprod; 1989 Jan; 4(1):1-12. PubMed ID: 2651469
[TBL] [Abstract][Full Text] [Related]
29. [Clinical evaluation of serum sialyl Lewis X-i (SLX) in diffuse panbronchiolitis].
Noguchi M; Nakatani T; Chohnabayashi N; Nakamori Y; Nakata K; Matsushita H; Tanimoto H
Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Mar; 27(3):317-25. PubMed ID: 2575680
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
[TBL] [Abstract][Full Text] [Related]
31. [Importance of CA-50 detection in malignant gynecologic tumors].
Indraccolo SR; Greco A; Cartechini MG; Compagnucci P
Minerva Ginecol; 1990 Dec; 42(12):507-9. PubMed ID: 2089292
[TBL] [Abstract][Full Text] [Related]
32. [Clinical evaluation of serum CA130 in patients with lung cancer].
Matsubara Y; Shiota T; Ishida H; Hanawa T; Yagi K; Kosaba S; Hatakenaka R; Funatsu T; Ikeda S
Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1557-65. PubMed ID: 2572655
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of serum sialyl Lewis(a), sialyl Lewis(x) and sialyl Tn antigens in blood from the tumor drainage vein of colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki M; Ohbatake M; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Tumour Biol; 2001; 22(2):115-22. PubMed ID: 11125284
[TBL] [Abstract][Full Text] [Related]
34. Sialyl Lewis-Xi antigen in patients with gynecologic tumors.
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O
Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
Kuzuya K; Nozaki M; Chihara T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
[TBL] [Abstract][Full Text] [Related]
36. [Clinical usefulness of tumor markers associated with pancreatic cancer].
Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
Rinsho Byori; 1994 Feb; 42(2):127-38. PubMed ID: 7908065
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Kiviranta A; Hallman K; Holm L; Weiner E; Tamsen L
Gynecol Oncol; 1990 Oct; 39(1):16-25. PubMed ID: 2227569
[TBL] [Abstract][Full Text] [Related]
38. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
40. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
